NEULAND LABORATORIES Financial Statement Analysis
|
||
|
The Revenues of NEULAND LABORATORIES have increased by 36.98% YoY .
The Earnings Per Share (EPS) of NEULAND LABORATORIES has increased by 39.94 % YoY. |
||
NEULAND LABORATORIES Last 5 Annual Financial Results
[BOM: 524558|NSE : NEULANDLAB]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹2,023 Cr | ₹1,477 Cr | ₹1,559 Cr | ₹1,191 Cr | ₹951 Cr |
| Expenses | ₹1,448 Cr | ₹1,154 Cr | ₹1,096 Cr | ₹919 Cr | ₹808 Cr |
| Operating Profit (Excl OI) | ₹574 Cr | ₹323 Cr | ₹463 Cr | ₹272 Cr | ₹143 Cr |
| Other Income | ₹30 Cr | ₹21 Cr | ₹13 Cr | ₹9.75 Cr | ₹2.08 Cr |
| Interest | ₹24 Cr | ₹8.30 Cr | ₹14 Cr | ₹13 Cr | ₹13 Cr |
| Depreciation | ₹92 Cr | ₹66 Cr | ₹60 Cr | ₹53 Cr | ₹49 Cr |
| Profit Before Tax | ₹489 Cr | ₹346 Cr | ₹401 Cr | ₹216 Cr | ₹82 Cr |
| Profit After Tax | ₹364 Cr | ₹260 Cr | ₹300 Cr | ₹164 Cr | ₹64 Cr |
| Consolidated Net Profit | ₹364 Cr | ₹260 Cr | ₹300 Cr | ₹164 Cr | ₹64 Cr |
| Earnings Per Share (Rs) | ₹283.71 | ₹202.74 | ₹233.89 | ₹127.45 | ₹49.74 |
| PAT Margin (%) | 17.99 | 17.61 | 19.25 | 13.73 | 6.71 |
| ROE(%) | 21.43 | 18.54 | 26.38 | 17.84 | 7.85 |
| ROCE(%) | 27.50 | 23.45 | 33.51 | 20.94 | 9.44 |
| Total Debt/Equity(x) | 0.10 | 0.09 | 0.06 | 0.12 | 0.28 |
Key Financials |
||
| Market Cap | : | ₹ 29,355.8 Cr |
| Revenue (TTM) | : | ₹ 2,371.8 Cr |
| Net Profit(TTM) | : | ₹ 497.8 Cr |
| EPS (TTM) | : | ₹ 388.9 |
| P/E (TTM) | : | 59.0 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NEULAND LABORATORIES | -0.1% | 20.3% | 71.5% |
| SUN PHARMACEUTICAL INDUSTRIES | 2% | -1.7% | 15.9% |
| DIVIS LABORATORIES | 6.5% | 14.8% | 48.4% |
| TORRENT PHARMACEUTICALS | 1.2% | -2.5% | 37.2% |
| CIPLA | -0.3% | -3.9% | -11.4% |
| DR REDDYS LABORATORIES | -2.2% | 1.5% | -8.3% |
| MANKIND PHARMA | 1.4% | -2.9% | -6.7% |
| LUPIN | 0.1% | -9.8% | 10.7% |
| ZYDUS LIFESCIENCES | 2.8% | 3.2% | 16% |
NEULAND LABORATORIES Revenues
[BOM: 524558|NSE : NEULANDLAB]
| Y-o-Y | 36.98 % |
| 5 Yr CAGR | 20.77 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹2,023 Cr | 36.98 | |
| Mar2025 | ₹1,477 Cr | -5.24 | |
| Mar2024 | ₹1,559 Cr | 30.84 | |
| Mar2023 | ₹1,191 Cr | 25.25 | |
| Mar2022 | ₹951 Cr | - | |
NEULAND LABORATORIES Operating Profit
[BOM: 524558|NSE : NEULANDLAB]
| Y-o-Y | 77.72 % |
| 5 Yr CAGR | 41.67 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹574 Cr | 77.72 | |
| Mar2025 | ₹323 Cr | -30.12 | |
| Mar2024 | ₹463 Cr | 70.17 | |
| Mar2023 | ₹272 Cr | 90.61 | |
| Mar2022 | ₹143 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 29.74 % |
| 5 Yr CAGR | 17.30 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 28.4% | 29.74 | |
| Mar2025 | 21.89% | -26.25 | |
| Mar2024 | 29.68% | 30.06 | |
| Mar2023 | 22.82% | 52.13 | |
| Mar2022 | 15% | - | |
NEULAND LABORATORIES Profit After Tax
[BOM: 524558|NSE : NEULANDLAB]
| Y-o-Y | 39.94 % |
| 5 Yr CAGR | 54.54 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹364 Cr | 39.94 | |
| Mar2025 | ₹260 Cr | -13.32 | |
| Mar2024 | ₹300 Cr | 83.51 | |
| Mar2023 | ₹164 Cr | 156.21 | |
| Mar2022 | ₹64 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 2.16 % |
| 5 Yr CAGR | 27.96 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 17.99 % | 2.16 | |
| Mar2025 | 17.61 % | -8.52 | |
| Mar2024 | 19.25 % | 40.20 | |
| Mar2023 | 13.73 % | 104.62 | |
| Mar2022 | 6.71 % | - | |
NEULAND LABORATORIES Earnings Per Share (EPS)
[BOM: 524558|NSE : NEULANDLAB]
| Y-o-Y | 39.94 % |
| 5 Yr CAGR | 54.54 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹284 | 39.94 | |
| Mar2025 | ₹203 | -13.32 | |
| Mar2024 | ₹234 | 83.52 | |
| Mar2023 | ₹127 | 156.23 | |
| Mar2022 | ₹50 | - | |
NEULAND LABORATORIES Return on Capital Employed (ROCE)
[BOM: 524558|NSE : NEULANDLAB]
| Y-o-Y | 17.27 % |
| 5 Yr CAGR | 30.64 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 27.5% | 17.27 | |
| Mar2025 | 23.45% | -30.02 | |
| Mar2024 | 33.51% | 60.03 | |
| Mar2023 | 20.94% | 121.82 | |
| Mar2022 | 9.44% | - | |
NEULAND LABORATORIES Share Price vs Sensex
| Current Share Price | : | ₹22,934.2 |
| Current MarketCap | : | ₹ 29,355.8 Cr |
| Updated EOD on | : | Aug 31,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NEULAND LABORATORIES | -0.1% |
20.3% |
71.5% |
| SENSEX | -0.5% |
-1.3% |
-5.4% |
NEULAND LABORATORIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 2% | 1.7% | 15.1% |
| BSE SMALLCAP SELECT INDEX | 0.2% | 5.6% | 16.5% |
| BSE 400 MIDSMALLCAP INDEX | 0% | 2.3% | 7.6% |
| BSE 250 SMALLCAP INDEX | -0.1% | 2.8% | 6% |
| BSE 1000 | -0.4% | 0.6% | 2.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY500 HEALTHCARE INDEX | 2.5% | 1.7% | 14.2% |
| NIFTY MIDSMALL HEALTHCARE | 1.7% | 1.4% | 17.4% |
| NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100 INDEX | 1% | 3.9% | 8.7% |
| NIFTY500 SHARIAH | 0.5% | 0.7% | -0.2% |
| NIFTY MIDSMALLCAP 400 | 0.3% | 2.5% | 9% |
You may also like the below Video Courses
FAQ about NEULAND LABORATORIES Financials
How the annual revenues of NEULAND LABORATORIES have changed ?
The Revenues of NEULAND LABORATORIES have increased by 36.98% YoY .
How the Earnings per Share (EPS) of NEULAND LABORATORIES have changed?
The Earnings Per Share (EPS) of NEULAND LABORATORIES has increased by 39.94 % YoY .
Check out Intrinsic Value of Peers of NEULAND LABORATORIES
Compare Stock Analytics of Peers of NEULAND LABORATORIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
